NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Emmessar Biotech & Nutrition : Q4 2024 Financial Quarterly Report : YoY Sales Down 76.27 %, QoQ Down 77.13 %

July 1, 2024July 1, 2024| adminadmin| 0 Comments| 2:30 am
Image is loading
Categories:

Share the post "Emmessar Biotech & Nutrition : Q4 2024 Financial Quarterly Report : YoY Sales Down 76.27 %, QoQ Down 77.13 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company’s sales declined by -76.27 % over the year, decrease in net sales/revenue by -77.13 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 16.67 %. Marginal decrease of -7.55% in other income during this quarter.
  • Profit over the Year and quarter: Significant improvement in profitability for Emmessar Biotech & Nutrition Ltd.. Notable increase of 87.31 % in net profit Year to Year, Emmessar Biotech & Nutrition Ltd.’s profitability increased by 186.05 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 86.84 % Year to Year. EPS increased by 173.08 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Emmessar Biotech & Nutrition Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 0.316 Cr Rs. 0.328 Cr Rs. 0.075 Cr -77.13 % -76.27 %
Expenses Rs. 0.47 Cr Rs. 0.53 Cr Rs. 0.47 Cr -11.32 % + 0 %
Operating Profit Rs. -0.15 Cr Rs. -0.2 Cr Rs. -0.4 Cr -100 % -166.67 %
OPM % -47.47 % -60.98 % -533.33 % -472.35 % -485.86 %
Other Income Rs. 0.42 Cr Rs. 0.53 Cr Rs. 0.49 Cr -7.55 % + 16.67 %
Interest Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Depreciation Rs. 0.02 Cr Rs. 0.02 Cr Rs. 0.02 Cr + 0 % + 0 %
Profit before tax Rs. 0.25 Cr Rs. 0.31 Cr Rs. 0.07 Cr -77.42 % -72 %
Tax % 17.57 % 56.27 % 450.75 % + 394.48 % + 433.18 %
Net Profit Rs. 0.2 Cr Rs. 0.13 Cr Rs. 0.37 Cr + 184.62 % + 85 %
EPS in Rs Rs. 0.38 Rs. 0.26 Rs. 0.71 + 173.08 % + 86.84 %


Today, we’re looking at Emmessar Biotech & Nutrition Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -76.27 %. However, it did see a marginal slip of -77.13 % from the previous quarter. Expenses decreased slightly by -11.32 % quarter-on-quarter, aligning with the annual rise of 0 %. Operating profit, while down -166.67 % compared to last year, faced a quarter-on-quarter dip of -100 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -485.86 %, but a shrinkage of -472.35 % sequentially. Other income fell by -7.55 % compared to the last quarter, despite an annual growth of 16.67 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 0 %. Profit before tax declined annually by -72 % but saw a reduction from the preceding quarter by -77.42 %.
Tax expenses as a percentage of profits increased slightly by 433.18 % compared to last year, with a more notable quarter-on-quarter increase of 394.48 %. Net profit rose by 85 % year-on-year but experienced a 184.62 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 86.84 % but a quarterly rise of 173.08 %. In summary, Emmessar Biotech & Nutrition Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 0.316 Cr Rs. 0.328 Cr Rs. 0.075 Cr -77.13 % -76.27 %
Expenses Rs. 0.47 Cr Rs. 0.53 Cr Rs. 0.47 Cr -11.32 % + 0 %
Operating Profit Rs. -0.15 Cr Rs. -0.2 Cr Rs. -0.4 Cr -100 % -166.67 %
Net Profit Rs. 0.2 Cr Rs. 0.13 Cr Rs. 0.37 Cr + 184.62 % + 85 %
EPS in Rs Rs. 0.38 Rs. 0.26 Rs. 0.71 + 173.08 % + 86.84 %


In reviewing Emmessar Biotech & Nutrition Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -76.27 % year-on-year, although there was a slight dip of -77.13 % from the previous quarter. Expenses rose by 0 % compared to the previous year, with a decrease of -11.32 % quarter-on-quarter. Operating Profit dropped by -166.67 % annually, and saw a -100 % decrease from the last quarter.
Net Profit showed yearly increase of 85 %, and experienced a 184.62 % increase from the previous quarter. Earnings Per Share (EPS) rose by 86.84 % annually, however rose by 173.08 % compared to the last quarter. In essence, while Emmessar Biotech & Nutrition Ltd. faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Emmessar Biotech & Nutrition “]

Related Post